Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Yan, Wensheng ^a   Jung, Yong Sam ^a   Zhang, Yanhong ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; MUTANT PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEASOME; PROTEIN BINDING; PROTEIN P53; RCHY1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PROTEIN DEGRADATION; TUMOR CELL LINE; UBIQUITINATION;

ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MUTANT PROTEINS; OXIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84905917295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103497     Document Type: Article

References (52)

1. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629. (Pubitemid 46744292)
2. Harms K, Nozell S, Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61: 822-842. (Pubitemid 38651002)
3. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, et al. (1993) Gain of function mutations in p53. Nat Genet 4: 42-46. (Pubitemid 23165910)
4. Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113: 433-439.
5. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
6. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860. (Pubitemid 40017690)
7. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. (Pubitemid 40017691)
8. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107: 246-251.
9. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165. (Pubitemid 46536647)
10. Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Cordeiro Y, et al. (2011) Colocalization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol 43: 60-64.
11. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485. (Pubitemid 29060623)
12. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, et al. (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16: 3269-3277. (Pubitemid 28330425)
13. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, et al. (1998) Activation of cmyc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18: 3735-3743. (Pubitemid 28287895)
14. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, et al. (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25: 10097-10110. (Pubitemid 41572755)
15. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, et al. (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22: 5667-5676. (Pubitemid 37102703)
16. Yan W, Liu G, Scoumanne A, Chen X (2008) Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 68: 6789-6796.
17. Yan W, Chen X (2009) Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem 284: 12178-12187.
18. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, et al. (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33: 442-451.
19. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26: 2220-2225. (Pubitemid 46536648)
20. Di Como CJ, Gaiddon C, Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19: 1438-1449. (Pubitemid 29046885)
21. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887. (Pubitemid 32156407)
22. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277: 18817-18826. (Pubitemid 34952441)
23. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503-29512. (Pubitemid 32043826)
24. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH (1998) The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18: 1517-1524. (Pubitemid 28100917)
25. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, et al. (2012) Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 7: e51426.
26. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, et al. (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 9: 577-588.
27. Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, et al. (2012) Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem 287: 28152-28162.
28. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, et al. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344. (Pubitemid 351717524)
29. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, et al. (2013) Chaperone-mediated autophagy degrades mutant p53. Genes Dev 27: 1718-1730.
30. Li D, Marchenko ND, Moll UM (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18: 1904-1913.
31. Rangel LP, Costa DC, Vieira TC, Silva JL (2014) The aggregation of mutant p53 produces prion-like properties in cancer. Prion 8. In press.
32. Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, et al. (2011) Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem 286: 17478-17486.
33. Emadi A, Gore SD (2010) Arsenic trioxide - An old drug rediscovered. Blood Rev 24: 191-199.
34. Yan W, Chen X, Zhang Y, Zhang J, Jung YS (2013) Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of DeltaNp63 protein. J Biol Chem 288: 2907-2913.
35. Yan W, Liu S, Xu E, Zhang J, Zhang Y, et al. (2013) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32: 599-609.
36. Jung YS, Liu G, Chen X (2010) Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. Mol Cell Biol 30: 1041-1048.
37. Jung YS, Qian Y, Yan W, Chen X (2013) Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. J Invest Dermatol 133: 1178-1187.
38. Zheng T, Wang J, Zhao Y, Zhang C, Lin M, et al. (2013) Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun 4: 2996.
39. Karsy M, Albert L, Murali R, Jhanwar-Uniyal M (2014) The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma. Tumour Biol 35: 4567-4580.
40. Lopes UG, Erhardt P, Yao R, Cooper GM (1997) p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896. (Pubitemid 27216701)
41. Choudhury S, Kolukula VK, Preet A, Albanese C, Avantaggiati ML (2013) Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle 12: 1022-1029.
42. Zheng G, Ning J, Yang YC (2007) PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53. Biochem Biophys Res Commun 364: 344-350. (Pubitemid 47633421)
43. Lee JT, Gu W (2010) The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 17: 86-92.
44. Shloush J, Vlassov JE, Engson I, Duan S, Saridakis V, et al. (2011) Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J Biol Chem 286: 4796-4808.
45. Peng Y, Chen L, Li C, Lu W, Chen J (2001) Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
46. Yan W, Liu S, Xu E, Zhang J, Zhang Y, et al. (2013) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32: 599-609.
47. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, et al. (2013) Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol 11: 22.
48. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, et al. (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res 71: 7168-7175.
49. Shen SC, Lee WR, Yang LY, Tsai HH, Yang LL, et al. (2012) Quercetin enhancement of arsenic-induced apoptosis via stimulating ROS-dependent p53 protein ubiquitination in human HaCaT keratinocytes. Exp Dermatol 21: 370-375.
50. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538-546. (Pubitemid 351627373)
51. Geoffroy MC, Jaffray EG, Walker KJ, Hay RT (2010) Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell 21: 4227-4239.
52. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555. (Pubitemid 351627374)